Jump to content

Fluvoxamine

From Pharmacopedia
Revision as of 15:06, 14 May 2026 by MediaWiki default (talk | contribs) (Assign pharmacological categories from List_of_CNS-active_medicines)
SSRI, Antidepressant
Fluvoxamine
Luvox

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions10 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC Strong 70 / 100
CPIC rec 8094271 [Strong]: Initiate therapy with recommended starting dose. CPIC pair-level B (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427]
Phenotype:CYP2D6 intermediate metabolizer monitor CPIC B 45 / 100
CPIC rec 8094275 [Moderate]: Initiate therapy with recommended starting dose. CPIC pair-level B (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427]
Phenotype:CYP2D6 poor metabolizer dose reduce 25 FDA Label 25 / 100
CPIC rec 8094277 [Optional]: Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6. CPIC pair-level B (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427] FDA labeling (Drug Interactions)
Phenotype:CYP2D6 ultrarapid metabolizer monitor CPIC B 5 / 100
CPIC rec 8094257 [No Recommendation]: No recommendation due to lack of evidence CPIC pair-level B (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427]
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP1A2 inhibitor strong Primary 90 / 100
FDA Drug Interactions Table: strong index inhibitor of CYP1A2.
Enzyme:CYP2C19 inhibitor strong Primary 90 / 100
FDA Drug Interactions Table: strong index inhibitor of CYP2C19.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Tizanidine pk raises via CYP1A2 Inferred 72 / 100
Fluvoxamine inhibits CYP1A2 (inhibitor_strong, intensity 90); Tizanidine is a substrate_major of CYP1A2 (intensity 80). Derived: Tizanidine exposure raised.
Inferred via Enzyme:CYP1A2 (exposure raised)
Lansoprazole pk raises via CYP2C19 Inferred 72 / 100
Fluvoxamine inhibits CYP2C19 (inhibitor_strong, intensity 90); Lansoprazole is a substrate_major of CYP2C19 (intensity 80). Derived: Lansoprazole exposure raised.
Inferred via Enzyme:CYP2C19 (exposure raised)
Omeprazole pk raises via CYP2C19 Inferred 72 / 100
Fluvoxamine inhibits CYP2C19 (inhibitor_strong, intensity 90); Omeprazole is a substrate_major of CYP2C19 (intensity 80). Derived: Omeprazole exposure raised.
Inferred via Enzyme:CYP2C19 (exposure raised)
Caffeine pk raises via CYP1A2 Inferred 72 / 100
Fluvoxamine inhibits CYP1A2 (inhibitor_strong, intensity 90); Caffeine is a substrate_major of CYP1A2 (intensity 80). Derived: Caffeine exposure raised.
Inferred via Enzyme:CYP1A2 (exposure raised)

Patient experience

Fluoxetine via Category:Antidepressants👤 exp n/a/5 outcome n/a (n=1)⚕️ exp 1.0/5 outcome +33.0 (n=1)

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
SSRI, Antidepressant
Common uses
Pharmacy
Pharmacology
Purported mechanism
Selective serotonin reuptake inhibitor